Novo Nordisk A/S (NYSE:NVO) Trading 0% Higher

Novo Nordisk A/S (NYSE:NVO - Get Free Report) rose 0% during mid-day trading on Friday . The company traded as high as $127.06 and last traded at $125.42. Approximately 1,360,576 shares were traded during trading, a decline of 73% from the average daily volume of 4,960,142 shares. The stock had previously closed at $125.40.

Analyst Upgrades and Downgrades

NVO has been the topic of a number of analyst reports. BMO Capital Markets initiated coverage on shares of Novo Nordisk A/S in a research report on Friday. They set an "outperform" rating and a $163.00 target price on the stock. UBS Group started coverage on shares of Novo Nordisk A/S in a research report on Tuesday, January 16th. They set a "neutral" rating on the stock. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $160.00 price target on shares of Novo Nordisk A/S in a research note on Monday, April 1st. Finally, Morgan Stanley started coverage on shares of Novo Nordisk A/S in a research note on Tuesday, January 23rd. They issued an "overweight" rating and a $120.00 target price on the stock. Two research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $133.60.

Novo Nordisk A/S Stock Performance

The stock's fifty day moving average is $125.71 and its two-hundred day moving average is $109.38. The firm has a market capitalization of $558.79 billion, a price-to-earnings ratio of 46.16, a price-to-earnings-growth ratio of 2.08 and a beta of 0.41. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.64 and a current ratio of 0.82.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last released its quarterly earnings results on Wednesday, January 31st. The company reported $0.71 earnings per share for the quarter, beating analysts' consensus estimates of $0.66 by $0.05. The business had revenue of $9.51 billion during the quarter, compared to analyst estimates of $9.14 billion. Novo Nordisk A/S had a net margin of 36.03% and a return on equity of 90.36%. Analysts forecast that Novo Nordisk A/S will post 3.32 earnings per share for the current year.

Novo Nordisk A/S Increases Dividend

The business also recently disclosed a Semi-Annual dividend, which was paid on Tuesday, April 2nd. Shareholders of record on Monday, March 25th were issued a dividend of $0.664 per share. This is a positive change from Novo Nordisk A/S's previous Semi-Annual dividend of $0.22. This represents a yield of 0.9%. The ex-dividend date of this dividend was Friday, March 22nd. Novo Nordisk A/S's dividend payout ratio (DPR) is currently 48.89%.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the stock. Cornerstone Planning Group LLC acquired a new position in shares of Novo Nordisk A/S in the 2nd quarter valued at about $29,000. First PREMIER Bank acquired a new position in shares of Novo Nordisk A/S in the 1st quarter valued at about $25,000. Tower Research Capital LLC TRC boosted its holdings in shares of Novo Nordisk A/S by 165.3% in the 1st quarter. Tower Research Capital LLC TRC now owns 199 shares of the company's stock valued at $32,000 after buying an additional 124 shares during the period. CNB Bank acquired a new position in shares of Novo Nordisk A/S in the 4th quarter valued at about $26,000. Finally, Pacific Center for Financial Services boosted its holdings in shares of Novo Nordisk A/S by 100.0% in the 3rd quarter. Pacific Center for Financial Services now owns 270 shares of the company's stock valued at $25,000 after buying an additional 135 shares during the period. 11.54% of the stock is owned by institutional investors and hedge funds.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.